Cargando…

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine

Objectives: The BNT162b2 mRNA COVID-19 vaccine has been found to be highly effective in preventing COVID-19 but is associated with increased reactogenicity. We aimed to examine the correlation between immunogenicity and reactogenicity of the BNT162b2 vaccine. Methods: Subjects without prior SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levy, Itzchak, Levin, Einav Gal, Olmer, Liraz, Regev-Yochay, Gili, Agmon-Levin, Nancy, Wieder-Finesod, Anat, Indenbaum, Victoria, Herzog, Karin, Doolman, Ram, Asraf, Keren, Halperin, Rebecca, Lustig, Yaniv, Rahav, Galia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412348/ https://www.ncbi.nlm.nih.gov/pubmed/36016109 http://dx.doi.org/10.3390/vaccines10081220

Ejemplares similares

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study
por: Shmueli, Einat S., et al.
Publicado: (2021)

Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study
por: Shacham-Shmueli, Einat, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
por: Lustig, Yaniv, et al.
Publicado: (2021)

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
por: Gilboa, Mayan, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
por: Nir, Omer, et al.
Publicado: (2022)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Missed opportunities for earlier diagnosis of HIV in patients who presented with advanced HIV disease: a retrospective cohort study
por: Levy, Itzchak, et al.
Publicado: (2016)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel
por: Gilboa, Mayan, et al.
Publicado: (2023)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
por: Regev-Yochay, Gili, et al.
Publicado: (2022)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
por: Joseph, Gili, et al.
Publicado: (2022)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
por: Regev-Yochay, Gili, et al.
Publicado: (2023)

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
por: Bergwerk, Moriah, et al.
Publicado: (2021)

Maternal and Neonatal Immune Responses Following COVID-19 Infection and Vaccinations in Pregnancy
por: Toussia-Cohen, Shlomi, et al.
Publicado: (2022)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
por: Barda, Noam, et al.
Publicado: (2022)

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy
por: Toussia-Cohen, Shlomi, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
por: Lipsitch, Marc, et al.
Publicado: (2021)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk
por: Shavit, Ronen, et al.
Publicado: (2021)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Complicated Pocket Infection in Patients Undergoing Lead Extraction: Characteristics and Outcomes
por: Milman, Anat, et al.
Publicado: (2023)

Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study
por: Lustig, Yaniv, et al.
Publicado: (2021)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders
por: Magen, Hila, et al.
Publicado: (2023)

Candida auris Infection Leading to Nosocomial Transmission, Israel, 2017
por: Belkin, Ana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ancbrpmje0aa6s0rtdsd55jbnk